6-溴-1H-吲哚-2-羧酸甲酯 | 372089-59-3

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-溴-1H-吲哚-2-羧酸甲酯
• 中文别名: 6-溴-2-吲哚羧酸乙酯；6-溴吲哚-2-甲酸甲酯
• 英文名称: methyl 6-bromo-1H-indole-2-carboxylate
• CAS: 372089-59-3
• 化学式: C₁₀H₈BrNO₂
• mdl: MFCD00590200
• 分子量: 254.083
• InChiKey: BUMYRKNZGPXFEG-UHFFFAOYSA-N

物化性质

• 沸点：
  386.2±22.0 °C(Predicted)
• 密度：
  1.629±0.06 g/cm3(Predicted)
• 溶解度：
  溶于丙酮。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境中使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 6-bromo-1h-indole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 6-bromo-1h-indole-2-carboxylate
CAS number: 372089-59-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8BrNO2
Molecular weight: 254.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-1H-吲哚-2-羧酸甲酯 在 盐酸 、 四(三苯基膦)钯 、 碘 、 碳酸氢钠 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.5h， 生成 2-hydroxy-9-(4-methoxyphenyl)chromeno[3,4-b]indol-6(7H)-one
  参考文献：
  名称：

  作为Lamellarin D类似物的chromeno [3,4- b ]吲哚的合成：一种新型DYRK1A抑制剂

  摘要：

  开发了取代的chromeno [3,4- b ]吲哚文库作为lamellarin等位基因。在涉及C的四步路径序列之后，由吲哚完成合成-3碘化，Suzuki交叉偶联反应和一锅脱保护/内酯化步骤。测试了二十种最终化合物以确定它们对拓扑异构酶I和激酶（Lamellarins的两种主要生物学活性）的活性。一种新合成的衍生物显示出强大的拓扑异构酶活性，可与参比化合物（例如喜树碱和lamellarin）相比，但激酶抑制作用较弱。其他两种先导化合物被鉴定为新的纳摩尔DYRK1A抑制剂，其他几种药物影响亚微摩尔范围内的激酶。这些结果将使我们能够使用chromeno [3,4- b ]吲哚作为药效团来开发有效治疗涉及DYRK1A的神经系统或肿瘤性疾病的方法。

  DOI：

  10.1016/j.ejmech.2012.01.040
• 作为产物：
  描述：

  4-溴-2-硝基苯甲醛 在 三乙烯二胺 、 copper(l) iodide 、 铁粉 、 溴化二甲基溴化锍 、 potassium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 3.58h， 生成 6-溴-1H-吲哚-2-羧酸甲酯
  参考文献：
  名称：

  CuI-catalyzed intramolecular cyclization of 3-(2-aminophenyl)-2-bromoacrylate: synthesis of 2-carboxyindoles

  摘要：

  A new approach was described for the synthesis of substituted 2-carboxyindole using 3-(2-aminophenyl)-2-bromo-acrylates through a CuI-catalyzed intramolecular coupling. The reactions were mild, rapid and with good to excellent yields. Crown Copyright (C) 2013 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.10.048

文献信息

• Synthesis of Indoles by Reductive Cyclization of Nitro Compounds Using Formate Esters as CO Surrogates
  作者：Manar Ahmed Fouad、Francesco Ferretti、Dario Formenti、Fabio Milani、Fabio Ragaini

  DOI：10.1002/ejoc.202100789

  日期：2021.9.14

  A very efficient, general and scalable protocol for the preparation of indoles and other N-heterocycles from suitably substituted nitroarenes using alkyl and phenyl formates as CO surrogates was described. Using phenyl formate, the products were isolated in yields often higher than those previously achieved by using gaseous CO. The mechanism of both the decarbonylation reaction of phenyl formate and

  描述了使用烷基和苯基甲酸酯作为 CO 替代物从适当取代的硝基芳烃制备吲哚和其他N-杂环的非常有效、通用和可扩展的方案。使用甲酸苯酯，产物的分离产率通常高于以前使用气态 CO 实现的产率。通过动力学和机理研究阐明了甲酸苯酯的脱羰反应和环化反应的机理。
• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。
• ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS
  申请人：Baryza Jeremy Lee

  公开号：US20160215288A1

  公开（公告）日：2016-07-28

  The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3′ end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. In some embodiments, the 3′ end of both the sense and anti-sense strand further comprise, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3′ end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the RNAi agent can be modified on one or both 5′ end. Optionally, the sense strand can comprise a 5′ end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference. The disclosure also pertains to methods of treating, ameliorating and preventing HBV in a patient involving the step of administering to the patient a therapeutic amount of a HBV RNAi agent.

  该披露涉及包含HBV RNAi药剂的组合物。在某些实施例中，HBV RNAi药剂包括一个正义链和一个反义链，每个链都是18个核苷酸长，并且这些链一起形成一个带有钝端的双链，其中至少一个链的3'端终止于磷酸酯或修饰的核苷酸间连接物，并且进一步包括，按照5'到3'的顺序：一个间隔物；第二个磷酸酯或修饰的核苷酸间连接物；和一个3'端帽。在某些实施例中，正义链和反义链的3'端进一步包括，按照5'到3'的顺序：一个间隔物；第二个磷酸酯或修饰的核苷酸间连接物；和一个3'端帽。这两个链可以具有相同或不同的间隔物、磷酸酯或修饰的核苷酸间连接物，和/或3'端帽。这些链可以是核糖核苷酸，或者，可选地，一个或多个核苷酸可以被修饰或替代。可选地，至少一个核苷酸包括一个修饰的核苷酸间连接物。可选地，RNAi药剂可以在一个或两个5'端上被修饰。可选地，正义链可以包括减少由该链介导的RNA干扰量的5'端帽。可选地，RNAi药剂附着在一个配体上。这种格式可以用来设计针对各种不同靶标和序列的RNAi药剂。该披露还涉及制备这种组合物的方法，以及这种组合物的方法和用途，例如，用于介导RNA干扰。该披露还涉及涉及将治疗量的HBV RNAi药剂给患者的步骤来治疗、改善和预防患者体内的HBV的方法。
• [EN] THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET MÉTHODES POUR TRAITER UNE INFECTION
  申请人：UNIV RUTGERS

  公开号：WO2019099402A1

  公开（公告）日：2019-05-23

  Disclosed herein are compounds of formula (I), or a salt thereof and compositions comprising compounds of formula I that exhibit antibacterial activities, when tested alone and/or in combination with a bacterial efflux pump inhibitor. Also disclosed are methods of treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I alone or in combination with the administration of a bacterial efflux pump inhibitor.

  本文披露了化合物的结构式（I）或其盐，以及包含表现出抗菌活性的化合物的组合物的组合物，当单独测试和/或与细菌外排泵抑制剂结合时。还披露了治疗或预防动物细菌感染的方法，包括向动物单独或与细菌外排泵抑制剂的给药结合给动物的结构式（I）的化合物。
• [EN] BACTERIAL EFFLUX PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE D'EFFLUX BACTÉRIEN
  申请人：UNIV RUTGERS

  公开号：WO2018218192A1

  公开（公告）日：2018-11-29

  Disclosed herein are compounds of formula I and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.

  本文披露了公式I的化合物及其盐。还披露了包含公式I化合物的组合物以及使用公式I化合物的方法。